WO2015007871A3 - Micro-arn et maladie inflammatoire à médiation auto-immune - Google Patents

Micro-arn et maladie inflammatoire à médiation auto-immune Download PDF

Info

Publication number
WO2015007871A3
WO2015007871A3 PCT/EP2014/065450 EP2014065450W WO2015007871A3 WO 2015007871 A3 WO2015007871 A3 WO 2015007871A3 EP 2014065450 W EP2014065450 W EP 2014065450W WO 2015007871 A3 WO2015007871 A3 WO 2015007871A3
Authority
WO
WIPO (PCT)
Prior art keywords
mediated inflammatory
immune mediated
micrornas
autoimmune
inflammatory disease
Prior art date
Application number
PCT/EP2014/065450
Other languages
English (en)
Other versions
WO2015007871A2 (fr
Inventor
Alessandra FERRARO
Francesco DOTTA
Manuela Battaglia
Guido SEBASTIANI
Original Assignee
Ospedale San Raffaele S.R.L.
Fondazione Umberto Di Mario Onlus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele S.R.L., Fondazione Umberto Di Mario Onlus filed Critical Ospedale San Raffaele S.R.L.
Publication of WO2015007871A2 publication Critical patent/WO2015007871A2/fr
Publication of WO2015007871A3 publication Critical patent/WO2015007871A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un inhibiteur de miR125a-5p et/ou miR 642a-5p et/ou miR 155- p et/ou miR 24-3p et miRNA 26a-5p et/ou une molécule miRNA 30b-5p ou leurs équivalents pour une utilisation médicale, notamment pour une utilisation dans la prévention et/ou le traitement de maladies inflammatoires à médiation auto-immune. L'invention concerne également un procédé d'identification des antagonistes des miARN ci-dessus ou équivalents, une composition pharmaceutique comprenant ledit miARN, des antagonistes, des miARN ou équivalents de ceux-ci et un procédé de diagnostic de la pathologie susmentionnée et un kit associé.
PCT/EP2014/065450 2013-07-17 2014-07-17 Micro-arn et maladie inflammatoire à médiation auto-immune WO2015007871A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176810 2013-07-17
EP13176810.3 2013-07-17

Publications (2)

Publication Number Publication Date
WO2015007871A2 WO2015007871A2 (fr) 2015-01-22
WO2015007871A3 true WO2015007871A3 (fr) 2015-03-19

Family

ID=48793956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/065450 WO2015007871A2 (fr) 2013-07-17 2014-07-17 Micro-arn et maladie inflammatoire à médiation auto-immune

Country Status (1)

Country Link
WO (1) WO2015007871A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014113089A2 (fr) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Polynucléotides capteurs de signal servant à modifier les phénotypes cellulaires
ES2810701T5 (es) 2015-10-05 2024-07-11 Modernatx Inc Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
SI3394093T1 (sl) * 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
US12042527B2 (en) 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
CN112190592B (zh) * 2020-08-25 2022-03-11 苏州市立医院(北区) miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029404A1 (fr) * 2009-09-11 2011-03-17 中国科学院上海生命科学研究院 Mir-125a pour réguler l'expression de rantes, composition et utilisation de celui-ci
WO2012037043A2 (fr) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Traitement d'une inflammation auto-immune en utilisant le mir-155

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029404A1 (fr) * 2009-09-11 2011-03-17 中国科学院上海生命科学研究院 Mir-125a pour réguler l'expression de rantes, composition et utilisation de celui-ci
WO2012037043A2 (fr) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Traitement d'une inflammation auto-immune en utilisant le mir-155

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BO-ZHI CHEN ET AL: "Identification of microRNAs expressed highly in pancreatic islet-like cell clusters differentiated from human embryonic stem cells", CELL BIOLOGY INTERNATIONAL, vol. 35, no. 1, 1 January 2011 (2011-01-01), pages 29 - 37, XP055072311, DOI: 10.1042/CBI20090081 *
DATABASE Geneseq [online] 12 May 2011 (2011-05-12), "Human miR-125a inhibitor sequence.", XP002731005, retrieved from EBI accession no. GSN:AZG42682 Database accession no. AZG42682 *
GUIDO SEBASTIANI ET AL: "Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity", DIABETES/METABOLISM RESEARCH AND REVIEWS, vol. 27, no. 8, 8 November 2011 (2011-11-08), pages 862 - 866, XP055145932, ISSN: 1520-7552, DOI: 10.1002/dmrr.1262 *
HEZOVA R ET AL: "microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 260, no. 2, 1 January 2010 (2010-01-01), pages 70 - 74, XP026799172, ISSN: 0008-8749, [retrieved on 20091025] *
RAM PYARE SINGH ET AL: "The role of miRNA in inflammation and autoimmunity", AUTOIMMUNITY REVIEWS, vol. 12, no. 12, 14 July 2013 (2013-07-14), pages 1160 - 1165, XP055145805, ISSN: 1568-9972, DOI: 10.1016/j.autrev.2013.07.003 *
SEBASTIANI G ET AL: "MicroRNAs as New Tools for Exploring Type 1 Diabetes: Relevance for Immunomodulation and Transplantation Therapy", TRANSPLANTATION PROCEEDINGS, vol. 43, no. 1, 3 November 2010 (2010-11-03), pages 330 - 332, XP028143686, ISSN: 0041-1345, [retrieved on 20101103], DOI: 10.1016/J.TRANSPROCEED.2010.09.104 *
XIA ZHAO ET AL: "MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, vol. 62, no. 11, 29 November 2010 (2010-11-29), pages 3425 - 3435, XP055145938, ISSN: 0004-3591, DOI: 10.1002/art.27632 *
YIPING MAO ET AL: "MicroRNAs as pharmacological targets in diabetes", PHARMACOLOGICAL RESEARCH, vol. 75, 28 June 2013 (2013-06-28), pages 37 - 47, XP055091416, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2013.06.005 *
YU-MENG SUN ET AL: "Diverse functions of miR-125 family in different cell contexts", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 6, no. 1, 15 January 2013 (2013-01-15), pages 6, XP021140304, ISSN: 1756-8722, DOI: 10.1186/1756-8722-6-6 *

Also Published As

Publication number Publication date
WO2015007871A2 (fr) 2015-01-22

Similar Documents

Publication Publication Date Title
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
WO2017062862A8 (fr) Compositions d'oligonucléotides et procédés associés
WO2015007871A3 (fr) Micro-arn et maladie inflammatoire à médiation auto-immune
WO2015106128A3 (fr) Agents d'arni modifiés
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
WO2016100347A3 (fr) Inhibiteurs à petite molécule de l'egfr et de pi3k
WO2015153959A3 (fr) Petites molécules inhibitrices de mcl-1 et leurs utilisations
EP3686200A3 (fr) Composés hétérocycles bicycliques et leurs utilisations en thérapie
CL2012003723A1 (es) Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2015077503A8 (fr) Composés inhibiteurs de l'autotaxine
WO2014179564A8 (fr) Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
EP2915818A3 (fr) Immunoglobuline à double domaine variable et ses utilisations
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CL2014002097A1 (es) Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central.
PL2736488T3 (pl) Kompozycje farmaceutyczne zawierające rifaksyminę, sposoby ich wytwarzania i ich zastosowanie do leczenia zakażeń pochwy
WO2015168521A3 (fr) Conjugués p97-polynucléotides
WO2015066426A3 (fr) Interventions à base d'angiopoïétine pour le traitement de la malaria cérébrale
WO2014151456A3 (fr) Traitement de maladies inflammatoires
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14742489

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14742489

Country of ref document: EP

Kind code of ref document: A2